Literature DB >> 33172544

Lysophosphatidylcholine aggravates contact hypersensitivity by promoting neutrophil infiltration and IL17 expression.

Mi Hye Song1, Anupriya Gupta1, Hye One Kim2, Kwonik Oh3.   

Abstract

Lysophosphatidylcholine (LPC) is a bioactive lysolipid known to contribute to the development of lung allergic diseases. However, it remains unknown whether LPC possesses proinflammatory properties in the skin as well. Here, we investigated this issue by injection of LPC into the murine contact hypersensitivity (CHS) model induced by 2,4-dinitrofluorobenzene (DNFB). LPC increased the expression of IL17, recruited more neutrophils, and eventually aggravated the CHS in the skins. Moreover, the effects of LPC diminished after neutralizing IL17 or depleting neutrophils. Mechanistically, LPC upregulated not only IL17 but also CXCL1 and CXCL2 in a G2A-dependent manner. Taken together, our study demonstrated that the upregulation of LPC could contribute to allergic skin inflammation by increasing IL17 expression and neutrophil recruitment via G2A receptor. [BMB Reports 2021; 54(4): 203-208].

Entities:  

Year:  2021        PMID: 33172544

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  3 in total

1.  Anti-Inflammatory Effects of Cicadidae Periostracum Extract and Oleic Acid through Inhibiting Inflammatory Chemokines Using PCR Arrays in LPS-Induced Lung inflammation In Vitro.

Authors:  Jung-Hee Hong; Young-Cheol Lee
Journal:  Life (Basel)       Date:  2022-06-08

2.  Distribution and Clinical Significance of IL-17A in Tumor-Infiltrating Lymphocytes of Non-Small Cell Lung Cancer Patients.

Authors:  Rui Xu; Xing Ke; Wenwen Shang; Shuna Liu; Xin Fu; Ting Wang; Shuxian Jin
Journal:  Pathol Oncol Res       Date:  2022-05-18       Impact factor: 2.874

3.  Lysophosphatidylcholine induces azurophil granule translocation via Rho/Rho kinase/F-actin polymerization in human neutrophils.

Authors:  Hwa-Yong Ham; Shin-Hae Kang; Dong-Keun Song
Journal:  Korean J Physiol Pharmacol       Date:  2022-05-01       Impact factor: 2.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.